Repligen Co. (NASDAQ:RGEN) Shares Bought by Sei Investments Co.

Sei Investments Co. boosted its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 12.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 219,604 shares of the biotechnology company's stock after purchasing an additional 24,662 shares during the period. Sei Investments Co. owned approximately 0.39% of Repligen worth $31,610,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of RGEN. Virtu Financial LLC purchased a new stake in shares of Repligen during the 4th quarter valued at approximately $251,000. Teacher Retirement System of Texas raised its position in Repligen by 229.1% in the fourth quarter. Teacher Retirement System of Texas now owns 9,775 shares of the biotechnology company's stock valued at $1,407,000 after purchasing an additional 6,805 shares during the period. Xponance Inc. lifted its stake in shares of Repligen by 7.1% in the 4th quarter. Xponance Inc. now owns 6,939 shares of the biotechnology company's stock valued at $999,000 after purchasing an additional 459 shares during the last quarter. Signaturefd LLC grew its holdings in shares of Repligen by 172.2% during the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 124 shares during the period. Finally, Polen Capital Management LLC increased its position in shares of Repligen by 14.6% during the 4th quarter. Polen Capital Management LLC now owns 40,556 shares of the biotechnology company's stock worth $5,838,000 after purchasing an additional 5,173 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Repligen

In related news, Director Margaret Pax purchased 250 shares of the company's stock in a transaction on Monday, March 17th. The shares were bought at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the purchase, the director now directly owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 1.20% of the company's stock.

Repligen Stock Down 2.7 %

NASDAQ RGEN traded down $3.71 on Friday, hitting $133.41. 856,653 shares of the stock were exchanged, compared to its average volume of 673,469. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $184.98. The company has a 50-day moving average price of $154.21 and a 200-day moving average price of $148.15. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The company has a market cap of $7.49 billion, a PE ratio of -261.59, a PEG ratio of 4.54 and a beta of 0.95.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.41 by $0.03. The firm had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. Sell-side analysts anticipate that Repligen Co. will post 1.72 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on RGEN shares. Royal Bank of Canada upped their target price on shares of Repligen from $203.00 to $205.00 and gave the company an "outperform" rating in a research report on Friday, February 21st. TD Cowen assumed coverage on shares of Repligen in a research report on Monday, February 10th. They set a "buy" rating and a $200.00 price objective for the company. JPMorgan Chase & Co. boosted their target price on Repligen from $190.00 to $200.00 and gave the company an "overweight" rating in a research report on Friday, February 21st. StockNews.com lowered Repligen from a "hold" rating to a "sell" rating in a research report on Friday, February 21st. Finally, Evercore ISI initiated coverage on Repligen in a report on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $178.64.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.